February 6, 2017 – Cambridge, UK - Inflazome, Ltd., a biotech company developing small molecule drugs that stop inflammation driven by our innate immune system, today opened a new office in Cambridge, UK to accommodate employees in the centre of the UK’s pharmaceutical industry.
Headquartered in Dublin, Ireland, Inflazome was founded in mid-2016 by leading academics Dr Matt Cooper, The University of Queensland (Australia) and Professor Luke O’Neill, Trinity College Dublin (Ireland), following a highly productive joint collaboration. Series A investors include Novartis Venture Fund and Fountain Healthcare Partners.
Inflazome is leading the way in developing orally available drugs to address clinical unmet needs in inflammatory diseases by targeting the inflammasome, which is now known to drive many chronic inflammatory conditions, including Parkinson’s, Alzheimer’s, Arthritis and Cardiovascular disease.
“Establishing the office in Cambridge connects Inflazome with the major pharma, biotech and clinical research hub in Europe,” said Dr Cooper.